Skip to main content
ELIXA trial: No cardiovascular risk with GLP-1 receptor agonist lixisenatide
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
ELIXA trial: No cardiovascular risk with GLP-1 receptor agonist lixisenatide
User login
Username
Password
Reset your password
Type
Lead
score